Pharma: Other News To Note
Tuesday, October 29, 2013
• H. Lundbeck A/S, of Valby, Denmark, said the FDA approved Sabril (vigabatrin) as add-on therapy for the treatment of refractory complex partial seizures in children 10 years and older who have inadequately responded to several other treatments and if the possible benefit outweighs the risks of vision loss.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.